Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Short Interest Update
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 631,600 shares, a growth of 140.0% from the April 30th total of 263,200 shares. Currently, 27.2% of the company’s stock are sold short. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is presently 0.6 days.
In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 25,000 shares of the stock in a transaction dated Tuesday, March 26th. The shares were acquired at an average price of $2.38 per share, for a total transaction of $59,500.00. Following the completion of the acquisition, the chief executive officer now owns 1,767 shares of the company’s stock, valued at approximately $4,205.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.07% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citigroup Inc. acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $34,000. CVI Holdings LLC acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Bank of New York Mellon Corp acquired a new stake in Tonix Pharmaceuticals during the fourth quarter valued at $38,000. 3.55% of the stock is owned by hedge funds and other institutional investors.
TNXP traded up $0.02 during trading on Monday, reaching $1.61. 1,300 shares of the stock traded hands, compared to its average volume of 641,947. The stock has a market cap of $9.68 million, a PE ratio of -0.06 and a beta of 1.90. Tonix Pharmaceuticals has a fifty-two week low of $1.53 and a fifty-two week high of $48.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.54 and a current ratio of 9.54. The firm’s 50-day moving average price is $1.86.
Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, May 13th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.11). On average, equities research analysts expect that Tonix Pharmaceuticals will post -4.05 EPS for the current year.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease.
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.